Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.lba1011 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. LBA1011-LBA1011 ◽

Cited By ~ 87

Author(s):

D. Miles ◽

A. Chan ◽

G. Romieu ◽

L. Y. Dirix ◽

J. Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Locally Recurrent

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

10.1158/0008-5472.sabcs11-s4-8 ◽

2011 ◽

Cited By ~ 19

Author(s):

L Gianni ◽

G Romieu ◽

M Lichinitser ◽

S Serrano ◽

M Mansutti ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

First Results ◽

Locally Recurrent

Faculty Opinions recommendation of AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717998592.793477025 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent

Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdh393 ◽

2004 ◽

Vol 15 (10) ◽

pp. 1527-1534 ◽

Cited By ~ 100

Author(s):

S. Chan ◽

N. Davidson ◽

E. Juozaityte ◽

F. Erdkamp ◽

A. Pluzanska ◽

...

Keyword(s):

Breast Cancer ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

First Line Therapy ◽

Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial

Annals of Oncology ◽

10.1093/annonc/mdp585 ◽

2010 ◽

Vol 21 (7) ◽

pp. 1430-1435 ◽

Cited By ~ 13

Author(s):

J.-U. Blohmer ◽

P. Schmid ◽

J. Hilfrich ◽

K. Friese ◽

A. Kleine-Tebbe ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

First Line Therapy ◽

2098 ORAL BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)70860-1 ◽

2007 ◽

Vol 5 (4) ◽

pp. 212-213 ◽

Cited By ~ 7

Author(s):

T. Pienkowski ◽

M. Pegram ◽

J. Forbes ◽

V. Valero ◽

W. Eiermann ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

Overall Survival Analysis

First Efficacy Results From the Turandot Phase III Trial Comparing Two Bevacizumab (BEV)-Containing Regimens as First-Line Therapy for HER2-Negative Metastatic Breast Cancer (MBC)

Annals of Oncology ◽

10.1093/annonc/mds393 ◽

2012 ◽

Vol 23 ◽

pp. ix116 ◽

Cited By ~ 5

Author(s):

C. Zielinski ◽

I. Lang ◽

M. Inbar ◽

Z. Kahan ◽

R. Greil ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

First Line Therapy ◽

Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer

European Journal of Cancer ◽

10.1016/j.ejca.2017.10.018 ◽

2018 ◽

Vol 90 ◽

pp. 153-155 ◽

Cited By ~ 6

Author(s):

David Miles ◽

David Cameron ◽

Magalie Hilton ◽

Josep Garcia ◽

Joyce O'Shaughnessy

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

Breast Cancer Research and Treatment ◽

10.1007/s10549-009-0498-7 ◽

2009 ◽

Vol 119 (1) ◽

pp. 127-136 ◽

Cited By ~ 62

Author(s):

Kenichi Inoue ◽

Kazuhiko Nakagami ◽

Mitsuhiro Mizutani ◽

Yasuo Hozumi ◽

Yasuhiro Fujiwara ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Trial Group ◽

First Line ◽

Her2 Positive ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

Trastuzumab Monotherapy

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study

The Breast ◽

10.1016/j.breast.2019.02.002 ◽

2019 ◽

Vol 45 ◽

pp. 22-28

Author(s):

A. Mavratzas ◽

S. Baek ◽

B. Gerber ◽

M. Schmidt ◽

V. Moebus ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Metastatic Breast ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽